Moffitt Cancer Center on the Forefront of Cancer Treatment with the TrueBeam™ Radiotherapy System from Varian Medical Systems

February 03, 2011

TAMPA, Fla. – Moffitt Cancer Center has acquired the  TrueBeam™ system with the potential for faster, more accurate and safer image-guided radiation treatment.  Moffitt has the first and only TrueBeam™ unit in the bay area.

The TrueBeam™ system, from Varian Medical Systems, was engineered from the ground up to deliver more powerful cancer treatments with pinpoint accuracy and precision. It uniquely integrates new imaging and motion management technologies within a sophisticated new architecture that makes it possible to deliver treatments more quickly, while monitoring and compensating for tumor motion. This opens the door to new possibilities for the treatment of lung, breast, prostate and head and neck cancers, as well as other cancers that are treatable with radiotherapy.

“We are very excited about expanding Moffitt’s technology and patient care capabilities through our continued relationship with Varian and TrueBeam™,” said Craig W. Stevens, M.D., Ph.D., chair of Moffitt’s Department of Radiation Oncology. “This new technology, combined with our physicians’ expertise in patient care, will allow us to treat cancers for cure that previously could not have been safely treated, and further personalize their treatment at the Moffitt Cancer Center.”

Faster Treatments

Dose delivery rates are significantly higher than any other linacs, thus the TrueBeam™ system can complete a treatment considerably faster. This makes it possible to offer greater patient comfort by shortening treatments and to improve precision by leaving less time for tumor motion during dose delivery. “Intelligent” automation further speeds treatments with an up to fivefold reduction in the number of steps needed for image guidance and dose delivery. Simple treatments that once took 15 minutes or more can be completed in less than two minutes once the patient is in position. Reducing treatment times also increases treatment accuracy, since patient movement is reduced

Enhanced Precision

The precision of the TrueBeam™ system is measured in increments of less than a millimeter. This accuracy is made possible by the system’s sophisticated architecture, which synchronizes imaging, patient positioning, motion management, beam shaping and dose delivery, performing accuracy checks every 10 milliseconds throughout the entire treatment. Critical data points are measured continually as a treatment progresses, ensuring that the system maintains a “true isocenter,” or focal point of treatment.

For lung and other tumors subject to respiratory motion, TrueBeam™ offers gated rotational intensity modulated radiotherapy (IMRT), which makes it possible to monitor patient breathing and compensate for tumor motion while quickly delivering dose during a continuous rotation around the patient.

Faster Imaging at Lower Doses

TrueBeam™ imaging technology can produce the three-dimensional images used to fine-tune tumor targeting in 60 percent less time. Additional functionality makes it possible to create images using 25 percent less X-ray dose. TrueBeam™ can be used for radiotherapy treatments including image-guided radiotherapy and radiosurgery (IGRT and IGRS), intensity-modulated radiotherapy (IMRT), rotational IMRT  radiotherapy and gated rotational IMRT treatments. 

About Moffitt Cancer Center

Located in Tampa, Florida, Moffitt Cancer Center  is an NCI Comprehensive Cancer Center - a designation that recognizes Moffitt’s excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 14 affiliates in Florida, one in Georgia, one in Pennsylvania and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer. Moffitt marks a very important anniversary this year – 25 years committed to one mission: to contribute to the prevention and cure of cancer.